On March 16, 2022, Apeiron's Board of Directors have come to this decision to promote Dr. Fred Aswad and Dr. Xiao-hui Gu as Senior Vice President, reporting to Dr. Mingxi Li, CEO of Apeiron.

The promotions were made in recognition of their contributions discovering and developing GTAEXS617, a selective CDK7 inhibitor. Earlier this month, we and Exscientia jointly made the decision officially nominating GTAEXS617 as our Development Candidate, entering GLP-Tox studies which achieved an important milestone of Apeiron.

Congratulation on their promotions and outstanding contributions to the company.